Zentalis Pharmaceuticals Gets Outperform Rating from Mizuho on Azenosertib Potential
Analyst highlights 75% upside potential ahead of key Phase 2 DENALI data readout for lead drug azenosertib.
/ 220 items
#andre↓
Kalaris Reinforces TH103’s Potential in Wet AMD Ahead of 2027 Catalyst
Kalaris reports 6-month follow-up data from 20 patients in TH103 Phase 1a trial. 29% of treatment-naïve patients remained injection-free for 6 months. Phase 1b/2 data expected H1 2027.
Intuitive Surgical Shares Plunge as Da Vinci Procedure Growth Slows Sharply
GLP-1 drugs and insurance uncertainty weigh on demand.
REGENXBIO Prices $100 Million Public Offering to Extend Cash Runway into 2028
Proceeds will support late-stage AAV gene therapy programs and extend cash runway to 2028.
GSK Discontinues Camlipixant After Mixed Phase 3 Results in Chronic Cough
The company will continue developing the drug for irritable bowel syndrome (IBS).
Stripe and Advent's $53B Bid for PayPal Deemed Inadequate by Board
The board has not yet formally responded to the proposal.